Prokaryotic expression and antimicrobial activity of human lysozyme-tachyplesins fusion protein

Chinese Journal of Biologicals

Volumn 23, Issue 8, 2010, Pages 829-833

  Ouyang, Ping ^a   Gao, Yu ^a   Lei, Lian Cheng ^a   Yin, Li Zi ^a   Jiang, Li Na ^a   Lv, Shuang ^a   Feng, Xin ^a   Han, Wen Yu ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Antimicrobial activity; Antimicrobial peptide; Lysozyme; Recombinant fusion proteins; Tachyplesins

Indexed keywords

HUMAN LYSOZYME TACHYPLESIN FUSION PROTEIN; HYBRID PROTEIN; LYSOZYME; TACHYPLESIN; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANTIMICROBIAL ACTIVITY; ARTICLE; ESCHERICHIA COLI; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PROKARYOTE; PROTEIN EXPRESSION; RESTRICTION MAPPING; STAPHYLOCOCCUS AUREUS;

PROKARYOTA; STAPHYLOCOCCUS AUREUS;

EID: 77956687557     PISSN: 10045503     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Deckers D, Vanlint D, Callewaert L, et al. Role of the lysozyme inhibitor Ivy in growth or survival of Escherichia coli and Pseudomonas aeruginosa bacteria in hen egg white and in human saliva and breast milk[J]. Appl Environ Microbiol, 2008,74(14):4434-4439.
2. Nakamura T, Furunaka H, Miyata T, et al. Tachyplesin, a class of antimicrobial peptide from the hemocytes of the horseshoe crab (Tachypleus tridentatus). Isolation and chemical structure[J]. J Biol Chem, 1988,263(32):16709-16713.
3. Laederach A, Andreotti AH, Fulton DB. Solution and micellebound structures of tachyplesin I and its active aromatic linear derivatives[J]. Biochemistry, 2002,41(41):12359-12368.
4. Chang J, Chen JC. Separation of recombinant human vasoactive intestinal peptide-humanin fusion protein via three different approaches[J]. Biochem Engi J, 2008,41(2):116-121.
5. Hu YL, Hu TS, Lin SK. The site-directed mutagenesis and expression of Cecropin B gene[J]. Pharm Biotechnol, 1999,6(4):193-197.
6. Bonomo RA. Multiple antibiotic-resistant bacteria in long-term-care facilities: An emerging problem in the practice of in factious diseases[J]. Clin Infect Dis, 2000,31(6):1414-1422.
7. Mangoni ML, Maisetta G, Di Luca M, et al. Comparative analysis of the bactericidal activities of amphibian peptide analogues against multidrug-resistant nosocomial bacterial strains[J]. Antimicrob Agents Chemother, 2008,52(1):85-91.
8. Herbert S, Bera A, Nerz C, et al. Molecular basis of resistance to muramidase and cationic antimicrobial peptide activity of lysozyme in staphylococci[J]. PLos Pathogens 2007,9(3):981-995.